MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by FUROSCIX® (furosemide injection)- an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind’s commercial and medical capabilities by integrating scPharmaceuticals’ experienced team into its existing infrastructure.
Read the full article: MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care //
Source: https://www.globenewswire.com/news-release/2025/10/07/3162600/29517/en/MannKind-Completes-Acquisition-of-scPharmaceuticals-Accelerating-Revenue-Growth-in-Cardiometabolic-Care.html